40. 高安動脈炎 Takayasu arteritis Clinical trials / Disease details
臨床試験数 : 25 / 薬物数 : 50 - (DrugBank : 21) / 標的遺伝子数 : 25 - 標的パスウェイ数 : 114
| No. | TrialID | Date_ enrollment  | Date_ registration  | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor  | Secondary_ sponsor  | Recruitment_ Status  | Inclusion_ agemin  | Inclusion_ agemax  | Inclusion_ gender  | Target_ size  | Phase | Countries | 
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05151848 (ClinicalTrials.gov)  | January 5, 2022 | 6/11/2021 | Comparison of Adalimumab and Tofacitinib in the Treatment of Active Takayasu Arteritis | An Open-label,Randomized, Controlled, Multicenter Study of Adalimumab and Tofacitinib in the Treatment of Active Takayasu Arteritis | Takayasu Arteritis | Drug: Adalimumab Injection;Drug: Tofacitinib 5 MG | Chinese SLE Treatment And Research Group | NULL | Recruiting | 18 Years | 65 Years | All | 100 | Phase 4 | China | 
| 2 | NCT04299971 (ClinicalTrials.gov)  | March 1, 2020 | 5/3/2020 | Efficiency of Methotrexate and Tofacitinib in Mild and Moderate Patients | Randomized Open-label Study in Mild and Moderate Patients With Takayasu Arteritis Between Methotrexate and Tofacitinib Based on the ECTA Cohort. | Takayasu Arteritis;Methotrexate;Inhibition;Treatment | Drug: Methotrexate Tablets;Drug: Tofacitinib tablet | Shanghai Zhongshan Hospital | NULL | Recruiting | 14 Years | 100 Years | All | 130 | Phase 4 | China |